Revenue from Contract with Customer, Excluding Assessed Tax in USD of Gain Therapeutics, Inc. from Q2 2021 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Summary
Gain Therapeutics, Inc. quarterly and annual Revenue from Contract with Customer, Excluding Assessed Tax history and change rate from Q2 2021 to 2023.
  • Gain Therapeutics, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending 31 Mar 2023 was $55,180, a 47% increase year-over-year.
  • Gain Therapeutics, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2023 was $55,180, a 58% decline from 2022.
  • Gain Therapeutics, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $132,640, a 0.96% decline from 2021.
Source SEC data
View on sec.gov
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Change (%)
Revenue from Contract with Customer, Excluding Assessed Tax, Annual (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Annual Change (%)

Gain Therapeutics, Inc. Quarterly Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2023 $55,180 +$17,642 +47% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q2 2022 $95,102 +$13,485 +17% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $37,538 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q3 2021 $15,971 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $81,617 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2

Gain Therapeutics, Inc. Annual Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $55,180 -$77,460 -58% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $132,640 -$1,288 -0.96% 01 Jan 2022 31 Dec 2022 10-K 26 Mar 2024 2023 FY
2021 $133,928 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.